These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12065789)

  • 1. Interpreting measures of treatment effect in cancer clinical trials.
    Case LD; Kimmick G; Paskett ED; Lohman K; Tucker R
    Oncologist; 2002; 7(3):181-7. PubMed ID: 12065789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endpoints for assessing drug activity in clinical trials.
    Pazdur R
    Oncologist; 2008; 13 Suppl 2():19-21. PubMed ID: 18434634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies.
    Roviello G; Andre F; Venturini S; Pistilli B; Curigliano G; Cristofanilli M; Rosellini P; Generali D
    Eur J Cancer; 2017 Nov; 86():257-265. PubMed ID: 29055841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials?
    A'Hern RP
    J Clin Oncol; 2016 Oct; 34(28):3474-6. PubMed ID: 27507871
    [No Abstract]   [Full Text] [Related]  

  • 5. Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.
    Pak K; Uno H; Kim DH; Tian L; Kane RC; Takeuchi M; Fu H; Claggett B; Wei LJ
    JAMA Oncol; 2017 Dec; 3(12):1692-1696. PubMed ID: 28975263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials.
    Sridhara R; Mandrekar SJ; Dodd LE
    Clin Cancer Res; 2013 May; 19(10):2613-20. PubMed ID: 23669421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Influence of handling censored data on estimating progression-free survival in cancer clinical trials (JCOG9913-A).
    Niimi M; Yamamoto S; Fukuda H; Ishizuka N; Akaza H
    Jpn J Clin Oncol; 2002 Jan; 32(1):19-26. PubMed ID: 11932358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perils of the Pathologic Complete Response.
    Rose BS; Winer EP; Mamon HJ
    J Clin Oncol; 2016 Nov; 34(33):3959-3962. PubMed ID: 27551115
    [No Abstract]   [Full Text] [Related]  

  • 9. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes and endpoints in trials of cancer treatment: the past, present, and future.
    Wilson MK; Karakasis K; Oza AM
    Lancet Oncol; 2015 Jan; 16(1):e32-42. PubMed ID: 25638553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to deal with measures of association: a short guide for the clinician.
    Knol MJ; Algra A; Groenwold RH
    Cerebrovasc Dis; 2012; 33(2):98-103. PubMed ID: 22156574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials.
    Aprile G; Fontanella C; Bonotto M; Rihawi K; Lutrino SE; Ferrari L; Casagrande M; Ongaro E; Berretta M; Avallone A; Rosati G; Giuliani F; Fasola G
    Oncotarget; 2015 Oct; 6(30):28716-30. PubMed ID: 26308250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?
    Amir E; Seruga B; Kwong R; Tannock IF; Ocaña A
    Eur J Cancer; 2012 Feb; 48(3):385-8. PubMed ID: 22115991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Average Hazard Ratio - A Good Effect Measure for Time-to-event Endpoints when the Proportional Hazard Assumption is Violated?
    Rauch G; Brannath W; Brückner M; Kieser M
    Methods Inf Med; 2018 May; 57(3):89-100. PubMed ID: 29719915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interpreting measures of treatment effect.
    Davies HT
    Hosp Med; 1998 Jun; 59(6):499-501. PubMed ID: 9775281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating a treatment effect: Choosing between relative and absolute measures.
    Sormani MP; Bruzzi P
    Mult Scler; 2017 Feb; 23(2):197-200. PubMed ID: 27207463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of censoring on conclusions of trials for women with metastatic breast cancer.
    Templeton AJ; Ace O; Amir E; Vera-Badillo F; Ocana A; Pond GR; Tannock IF
    Eur J Cancer; 2015 Apr; 51(6):721-4. PubMed ID: 25728257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Activity, objective response, and WHO and RECIST (Response Evaluation Criteria In Solid Tumor) evaluation criteria].
    De Angelis V
    Suppl Tumori; 2004; 3(4):S7-9. PubMed ID: 15206198
    [No Abstract]   [Full Text] [Related]  

  • 19. [Survival and quality of life: integrated endpoints].
    Costantini M
    Suppl Tumori; 2004; 3(4):S10-1. PubMed ID: 15206199
    [No Abstract]   [Full Text] [Related]  

  • 20. A Most Odd Ratio:: Interpreting and Describing Odds Ratios.
    Persoskie A; Ferrer RA
    Am J Prev Med; 2017 Feb; 52(2):224-228. PubMed ID: 27639787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.